Quick Overview: Pipeline Highlights RP11 Program: Positive reception from the scientific community following recent presentations in the U.S. ... PYC Therapeutics CEO Rohan Hockings joins ausbiz Key highlights from Rohan Hockings' (CEO of

Pyc Therapeutics Investor Update Clinical - Detailed Overview & Context

Pipeline Highlights RP11 Program: Positive reception from the scientific community following recent presentations in the U.S. ... PYC Therapeutics CEO Rohan Hockings joins ausbiz Key highlights from Rohan Hockings' (CEO of PYC Investor Presentation of PYC 003 ADPKD Drug Safety & Efficacy on 28 Nov 2024 What if a tiny $20M biotech just created a breakthrough that can detect cancer in the brain with 92% accuracy… and the market is ...

Photo Gallery

PYC Therapeutics Investor Update | Clinical Milestones Met for RNA Platform Eye Disease Trials
PYC 2026 Q1 Investor Update 24 Feb 2026
PYC Therapeutics Investor Webinar | Oct 13, 2025
PYC 2025 Q4 Investor Webinar: RP11 $M Deal Near Term, $Billions Deal on PKD Drug in 12+ Months
PYC Q3 Investor Call Presentation 27.09.2023
PYC Investor Update Presentation on 30 May 2025
Cracking the Code: How PYC Therapeutics (ASX: PYC) is Tackling Rare Diseases
PYC Investor Update Presentation 17.02.2023
PYC Investor Update Q3 2025 - Annual Earning Could Exceed US$18 Billion by 2028, $28 Billion by 2029
PYC Therapeutics CEO Rohan Hockings joins ausbiz
PYC AGM 18 Nov 2025, Progress Report, Outlook for 2026-27, New Est. Annual Earnings US$30Billion
PYC Investor Update on ADOA Drug Program 05.10.2023
Sponsored
Sponsored
View Main Result
Sponsored
Sponsored